p53 family members and chemoresistance in cancer: What we know and what we need to know

Drug Resistance Updates

Volumn 6, Issue 6, 2003, Pages 323-328

  Gasco, Milena ^a   Crook, Tim ^b  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Chemotherapy; Drug resistance; p53; p73

Indexed keywords

ANTINEOPLASTIC AGENT; MUTANT PROTEIN; PROTEIN P53; PROTEIN P73; TRANSCRIPTION COACTIVATOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER; CYTOTOXICITY; DRUG RESISTANCE; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; HUMAN; PARALOGY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN VARIANT; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION REGULATION;

EID: 0842269242     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2003.11.001     Document Type: Article

References (61)

1. Basu, S., Totty, N.F., Irwin, M.S., Sudol, M., Downward, J., 2003. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol. Cell 11, 11-23.
2. Bergamaschi, D., Gasco, M., Hiller, L., et al., 2003. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3. 387-402.
3. Blandino, G., Levine, A.J., Oren, M., 1999. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18, 477-485.
4. Brooks, L.A., Sullivan, A., O'Nions, J., et al., 2002. E7 proteins from oncogenic human papillomavirus types transactivate p73. Br. J. Cancer 86, 263-268.
5. Broxterman, H.J., Lankelma, J., Hoekman, K., 2003. Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences. Drug Resist. Update 6, 111-127.
6. Burns, T.F., Fei, P., Scata, K.A., Dicker, D.T., El-Deiry, W.S., 2003. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol. Cell. Biol. 23, 5556-5571.
7. Bykov, V.J., Selivanova, G., Wiman, K.G., 2003. Small molecules that reactivate mutant p53. Eur. J. Cancer 39, 1828-1834.
8. Costanzo, A., Merlo, P., Pediconi, N., et al., 2002. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell 9, 175-186.
9. DiComo, C.J., Gaiddon, C., Prives, C., 1999. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19, 1438-1449.
10. D'Orazi, G., Cecchinelli, B., Bruno, T., et al., 2002. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4, 11-19.
11. El-Hizawi, S., Lagowski, J.P., Kulesz-Martin, M., Albor, A., 2002. Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins. Cancer Res. 62, 3264-3270.
12. Fillippovich, I., Sorokina, N., Gatei, M., et al., 2001. Transactivation-deficient p73a (p73Dexon2) inhibits apoptosis and competes with p53. Oncogene 20, 514-522.
13. Fojo, T., 2002. p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. Drug Resist. Update 5, 209-216.
14. Frasca, F., Vella, V., Aloisi, A., Mandarino, A., Mazzon, E., Vigneri, R., Vigneri, P., 2003. p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res. 63, 5829-5837.
15. Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., Prives, C., 2001. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21, 1874-1877.
16. Geisler, S., Lonning, P.E., Aas, T., Johnsen, H., Fluge, O., Haugen, D.F., Lillehaug, J., Akslen, L.A., Borresen-Dale, A.-L., 2001. Influence of TP53 gene alterations and c-erb-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61, 2505-2512.
17. Gong, J., Costanzo, A., Yang, H.Q., Melino, G., Kaelin, Jr., W.G., Levrero, M., Wang, J.Y.J., 1999. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399, 806-809.
18. Grob, T.J., Novak, U., Maisse, C., et al., 2001. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 8, 1213-1223.
19. Hofman, T.G., Moller, A., Sirma, H., Zentgraft, H., Taya, Y., Droge, W., Will, H., Schmitz, M.L., 2001. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4, 1-10.
20. Huang, S.-M., Schonthal, A.H., Stallcup, M.R., 2001. Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1. Oncogene 20, 2134-2143.
21. Irwin, M.S., Kaelin, W.G., 2001. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ. 12, 337-349.
22. Irwin, M.S., Kondo, K., Marin, M.C., Cheung, L.S., Hahn, W.C., Kaelin, W.G., 2003. Chemosensitivity linked to p73 function. Cancer Cell 3, 403-410.
23. Johnstone, R.W., Ruefli, A.A., Lowe, S.W., 2002. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164.
24. Kaghad, M., Bonnet, H., Yang, A., et al., 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809-819.
25. Kandioler-Eckersberger, D., Ludwig, C., Rudas, M., et al., 2000. TP53 mutation and p53 over-expression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin. Cancer Res. 6, 50-56.
26. Kim, E.J., Park, J.S., Um, S.J., 2002. Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo. J. Biol. Chem. 277, 32020-32028.
27. Kumar, A., Zhao, Y., Meng, G., et al., 2002. Human papilloma virus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol. Cell. Biol. 22, 5801-5812.
28. Lill, N.L., Grossman, S.R., Ginsberg, D., DeCaprio, J., Livingston, D.M., 1997. Binding and modulation of p53 by p300/CBP coactivators. Nature 387, 823-827.
29. Marin, M.C., Jost, C.A., Brooks, L.A., et al., 2000. A common polymorphism acts as an intragenie modifier of mutant p53 behaviour. Nat Genet. 25, 47-54.
30. Martinez-Delgado, B., Melendez, B., Cuadros, M., Garcia, M.J., Nomdedeu, J., Rivas, C., Fernandez-Piqeras, J., Benitez, J., 2002. Frequent inactivation of the TP73 gene by abnormal methylation or LOH in non-Hodgkin's lymphoma. Int. J. Cancer 102, 15-19.
31. McCaffrey, A.P., Meuse, L., Pham, T.T., Conklin, D.S., Hannon, G.J., Kay, M.A., 2002. RNA interference in adult mice. Nature 418, 38-39.
32. Melino, G., De Laurenzi, V., Vousden, K.H., 2002. p73: Friend or foe in tumorigenesis. Nat. Rev. Cancer 2, 605-615.
33. Monti, P., Campomenosi, P., Ciribilli, Y., et al., 2003. Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene 22, 5252-5260.
34. Miyazaki, K., Ozaki, T., Kato, C., et al., 2003. A novel HECT-type E3 ubiquitin ligase, NEDL2, stabilizes p73 and enhances its transcriptional activity. Biochem. Biophys. Res. Commun. 308, 106-113.
35. O'Nions, J., Brooks, L.A., Sullivan, A., et al., 2001. p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. Br. J. Cancer 85, 1551-1556.
36. Ono, Y., Nonomura, N., Harada, Y., et al., 2001. Loss of p73 induction in a cisplatin-resistant bladder cancer cell line. Mol. Urol. 5, 25-30.
37. Peng, Y.C., Kuo, F., Breiding, D.E., Wang, Y.F., Mansur, C.P., Androphy, E.J., 2001. AMF1 (GPS2) modulates p53 transactivation. Mol. Cell. Biol. 21, 5913-5924.
38. Perez, R.P., Hamilton, T.C., Ozols, R.F., Young, R.C., 1993. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer (Phila.) 71, 1571-1580.
39. Pugachava, E.N., Ivanov, A.V., Kravchenko, J.E., Kopnin, B.P., Levine, A.J., Chumakov, P.M., 2002. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluouracil. Oncogene 21, 4595-4600.
40. Rahko, E., Blanco, G., Soini, Y., Bloigu, R., Jukkola, A., 2003. A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur. J. Cancer 39, 447-453.
41. Roninson, I.B., 2002. Tumor senescence as a determinant of drug response in vivo. Drug Resist. Update 5, 204-208.
42. Roth, J., Lenz-Bauer, C., Contente, A., Lohr, K., Koch, P., Bernard, S., Dobbelstein, M., 2003. Reactivation of mutant p53 by a one-hybrid adaptor protein. Cancer Res. 63, 3904-3908.
43. Samuels-Lev, Y., O'Connor, D.J., Bergamaschi, D., et al., 2001. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8, 781-794.
44. Samuels-Lev, Y., Bergamaschi, D., O'Neil, N.J., et al., 2003. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat. Genet. 33, 162-167.
45. Schmitt, C.A., Lowe, S.W., 2001. Apoptosis is critical for drug response in vivo. Drug Resist. Update 4, 303-313.
46. Schmitt, C.A., Fridman, J.S., Yang, M., Lee, S., Baranov, E., Hoffman, R.M., Lowe, S.W., 2002. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346.
47. Shimodaira, H., Yoshioka-Yamashita, A., Kolodner, R.D., Wang, J.Y., 2003. Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc. Natl. Acad. Sci. U.S.A. 100, 2420-2425.
48. Sigal, A., Rotter, V., 2000. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60, 6788-6793.
49. Siu, L.L., Chan, J.K., Wong, K.F., Kwong, Y.L., 2002. Specific patterns of gene methylation in natural killer cell lymphomas: p73 is consistently involved. Am. J. Pathol. 160, 59-66.
50. Soussi, T., Beroud, C., 2001. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer 1, 233-240.
51. Strano, S., Munarriz, E., Rossi, M., et al., 2000. Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem. 275, 29503-29512.
52. Strano, S., Fontemaggi, G., Costanzo, A., et al., 2002. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J. Biol. Chem. 277, 18817-18826.
53. Stuart, G.C.E., 2003. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol. Oncol. 90, S8-S15.
54. Temam, S., Flahault, A., Perie, S., et al., 2000. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J. Clin. Oncol. 18, 385-394.
55. Tsang, W.P., Chau, S.P., Fung, K.P., Kong, S.K., Kwok, T.T., 2003. Modulation of multidrug resistance-associated protein 1 (MRP1) by p53 mutant in Saos-2 cells. Cancer Chemother. Pharmacol. 51, 161-166.
56. Yang, A., Kaghad, M., Wang, Y., et al., 1997. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2, 305-316.
57. Zaffaroni, N., Daidone, M.G., 2002. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist. Update 5, 65-72.
58. Zaika, A., Slade, N., Erster, S.H., et al., 2002. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is upregulated in human tumors. J. Exp. Med. 196, 765-780.
59. Zalcenstein, A., Stambolsky, P., Weisz, L., et al., 2003. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 22, 5667-5676.
60. Zeng, X., Chen, L., Jost, C.A., Maya, R., Keller, D., Wang, X., Kaelin, W.G., Oren, M., Chen, J., Lu, H., 1999. MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol. 19, 3257-3266.
61. Zeng, S.X., Dai, M.S., Keller, D.M., Lu, H., 2002. SSRP1 functions as a co-activator of the transcriptional activator p63. EMBO J. 21, 5487-5497.